OraSure Technologies, Inc. Earnings Recaps
Q1 2026
May 8, 2026
OraSure Technologies shares rose 4.3% following a quarter that delivered revenue growth and gross margin expansion, supported by progress in near-shoring initiatives and product pipeline advancement that appear to have reassured investors about future prospects.
Key takeaways
- Total revenue reached $27.9 million, above the midpoint of guidance, with a 4% sequential increase.
- Diagnostics revenue grew 12% sequentially to $16.9 million, split evenly between U.S. and international markets.
- Sample Management Solutions revenue remained flat at $9.1 million, held back by muted NIH-related demand.
- Gross margin improved to 43.4% on a non-GAAP basis, driven by in-sourcing production and manufacturing efficiencies.
- R&D expense rose to $13.7 million due to launch preparations for two FDA-pending products expected to drive growth starting in the second half of 2026.
Q3 2025
Nov 6, 2025
OraSure Technologies reported Q3 2025 total revenues of $27.1 million, reflecting a strategic repositioning amid mixed market conditions, while also highlighting a significant acquisition aimed at expanding their diagnostic portfolio.
Key takeaways
- Total revenue for Q3 2025 was $27.1 million, driven by Diagnostics revenues of $14.5 million and Sample Management revenues of $10.3 million.
- The company signed a definitive agreement to acquire BioMedomics, adding a rapid test for sickle cell disease to its international diagnostic portfolio.
- U.S. Diagnostics revenue anticipated to decline slightly, while International Diagnostics expected to see a 20% year-over-year reduction, reflecting funding challenges in public health.
- The renewal of the "Together Take Me Home" program aims to further support HIV self-testing initiatives, contributing an expected $1.8 million in revenue for Q4.
- Confidence remains for 2026 growth, particularly in Sample Management, driven by advancements in genomics and increased adoption in international markets.